Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular comorbidities in spondyloarthritis

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

In recent years, many researchers have focused on the development of comorbidities associated with axial spondyloarthritis. Hypertension, smoking, dyslipidemia, diabetes mellitus, obesity, and the presence of inflammation, which is a well-known risk factor, increase cardiovascular comorbidities. Previous studies reported that HLA-B27 might be a genetic risk factor for various cardiac conditions. In the treatment and follow-up, raising the awareness of cardiovascular risk and guiding clinical practice and future research in rheumatic and musculoskeletal diseases should be aimed. There is consensus that cardiovascular risks should be evaluated periodically in these patients, particularly during the course of treatment. A decision regarding the selection and follow-up protocols of the drugs should be made considering all the risks and benefits in spondyloarthropathies. In this review, we discussed the recommendations and practices for the management of cardiovascular comorbidities in axial spondyloarthritis.

Key Points

• The risk of cardiovascular morbidity and mortality is increased in axial spondyloarthritis.

• Higher disease activity increases cardiovascular risk factors.

• Axial spondyloarthritis patients should be carefully monitored for signs of cardiovascular events as this is necessary to ensure that patients are treated appropriately and awareness should be raised in all patients.

• Reducing the activity of the underlying disease with an appropriate and early treatment will also reduce the risk of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rudwaleit M (2019) Classification and epidemiology of spondyloarthritis. In: Hochberg MC, Gravallase EM, Silman AJ, Smolen JS,Weinblatt ME, Weisman MH (eds.) Rheumatology, Elsevier, 7th edn pp 993–997

  2. Wysham KD, Gensler LS (2019) Clinical features of axial spondyloarthritis. In: Hochberg MC, Gravallase EM, Silman AJ, Smolen JS,Weinblatt ME, Weisman MH (eds.) Rheumatology, Elsevier, 7th edn. pp 1002–1008

  3. Cardelli C, Monti S, Terenzi R, Carli L (2021) One year in review 2021: axial spondyloarthritis. Clin Exp Rheumatol 39:1272–1281. https://doi.org/10.55563/clinexprheumatol/jlyd1l

    Article  PubMed  Google Scholar 

  4. Zhao SS, Ermann J, Xu C (2019) Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology (Oxford) 58:2025–2030. https://doi.org/10.1093/rheumatology/kez171

    Article  CAS  PubMed  Google Scholar 

  5. Toussirot E (2021) The risk of cardiovascular diseases in axial spondyloarthritis. Current insights Front Med (Lausanne) 8(8):782150. https://doi.org/10.3389/fmed.2021.782150

    Article  PubMed  Google Scholar 

  6. Moltó A, Etcheto A, van der Heijde D et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75:1016–1023. https://doi.org/10.1136/annrheumdis-2015-208174

    Article  CAS  PubMed  Google Scholar 

  7. Kerola AM, Kazemi A, Rollefstad S (2022) All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford) 4:keac210. https://doi.org/10.1093/rheumatology/keac210

    Article  Google Scholar 

  8. Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775

    Article  CAS  PubMed  Google Scholar 

  9. Drosos GC, Vedder D, Houben E et al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81:768–779. https://doi.org/10.1136/annrheumdis-2021-221733

    Article  CAS  PubMed  Google Scholar 

  10. van der Heijde D, Ramiro S, Landewé R et al (2016) update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978–991. https://doi.org/10.1136/annrheumdis-2016-210770

    Article  Google Scholar 

  11. Kim JH, Choi IA (2021) Cardiovascular morbidity and mortality in patients with spondyloarthritis: a meta-analysis. Int J Rheum Dis 24:477–486. https://doi.org/10.1111/1756-185X.13970

    Article  CAS  PubMed  Google Scholar 

  12. Martín-Martínez MA, Castañeda S, González-Juanatey C et al (2019) Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. Clin Exp Rheumatol 37:731–739

    PubMed  Google Scholar 

  13. Martín-Martínez MA, Castañeda S, Sánchez-Alonso F et al (2021) Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up. Rheumatology (Oxford) 60:2906–2915. https://doi.org/10.1093/rheumatology/keaa737

    Article  PubMed  Google Scholar 

  14. Bengtsson K, Forsblad-d’Elia H, Lie E et al (2017) Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 18(19):102. https://doi.org/10.1186/s13075-017-1315-z

    Article  Google Scholar 

  15. López-Medina C, Jiménez-Gómez Y, Moltó A et al (2018) Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: an ancillary study of the ASAS-COMOSPA project. Joint Bone Spine 85:447–453. https://doi.org/10.1016/j.jbspin.2017.07.006

    Article  PubMed  Google Scholar 

  16. Çay HF, Alkan Melikoğlu M, Yurdakul FG et al (2023) Real-life data on the comorbidities in spondyloarthritis from our multicenter nationwide registry: BioStaR Arch Rheumatol. https://doi.org/10.46497/ArchRheumatol.2023.9793

  17. Ferraz-Amaro I, Rueda-Gotor J, Genre F et al (2021) Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis 28(13):1759720X211033755. https://doi.org/10.1177/1759720X211033755

    Article  Google Scholar 

  18. Navarini L, Currado D, Marino A et al (2022) Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci Rep 7(12):7498. https://doi.org/10.1038/s41598-022-11640-8

    Article  CAS  Google Scholar 

  19. Bhattad PB, Kulkarni M, Patel PD, Roumia M (2022) Cardiovascular morbidity in ankylosing spondylitis: a focus on inflammatory cardiac disease. Cureus 14:e25633. https://doi.org/10.7759/cureus.25633

    Article  PubMed  PubMed Central  Google Scholar 

  20. Forsblad-d’Elia H, Wallberg H, Klingberg E et al (2013) Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study. BMC Musculoskelet Disord 14:237

    Article  PubMed  PubMed Central  Google Scholar 

  21. Bengtsson K, Forsblad-d’Elia H, Lie E et al (2018) Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis 77:541–548. https://doi.org/10.1136/annrheumdis-2017-212189

    Article  CAS  PubMed  Google Scholar 

  22. Bengtsson K, Klingberg E, Deminger A et al (2019) Cardiac conduction disturbances in patients with ankylosing spondylitis: results from a 5-year follow-up cohort study. RMD Open 13(5):e001053. https://doi.org/10.1136/rmdopen-2019-001053

    Article  Google Scholar 

  23. Romand X, Adeline F, Dalecky M et al (2022) Systematic assessment of heart valves and cardiac function by echocardiography in axial spondyloarthritis: a systematic review and meta-analysis. Joint Bone Spine 89:105375. https://doi.org/10.1016/j.jbspin.2022.105375

    Article  PubMed  Google Scholar 

  24. Derakhshan MH, Goodson NJ, Packham JC et al (2019) Increased risk of hypertension associated with spondyloarthritis disease duration: results from the ASAS-COMOSPA study. J Rheumatol 46:701–709. https://doi.org/10.3899/jrheum.180538

    Article  PubMed  Google Scholar 

  25. Chou CH, Lin MC, Peng CL et al (2014) A nationwide population-based retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol 43:132–136. https://doi.org/10.3109/03009742.2013.822097

    Article  PubMed  Google Scholar 

  26. Feng KM, Chien WC, Chen YH et al (2022) Increased risk of acute coronary syndrome in ankylosing spondylitis patients with uveitis: a population-based cohort study. Front Immunol 10(13):890543. https://doi.org/10.3389/fimmu.2022.890543

    Article  CAS  Google Scholar 

  27. González Mazón I, Rueda-Gotor J, Ferraz-Amaro I et al (2021) Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Semin Arthritis Rheum 51:395–403. https://doi.org/10.1016/j.semarthrit.2021.02.003

    Article  PubMed  Google Scholar 

  28. Rueda-Gotor J, Ferraz-Amaro I, Genre F et al (2022) Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Semin Arthritis Rheum 55:152037. https://doi.org/10.1016/j.semarthrit.2022.152037.

  29. Ben Tekaya A, Boukriba S, Fendri A et al (2022) Endothelial dysfunction and increased carotid intima-media thickness in patients with spondyloarthritis without traditional cardiovascular risk factors. RMD Open 8:e002270. https://doi.org/10.1136/rmdopen-2022-002270

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099–1112. https://doi.org/10.1016/0092-8674(90)90512-d

    Article  CAS  PubMed  Google Scholar 

  31. Poddubnyy D, Sieper J, Arévalo M et al (2020) Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: data from COMOSPA. Joint Bone Spine 87:445–448. https://doi.org/10.1016/j.jbspin.2020.03.012

    Article  CAS  Google Scholar 

  32. Lai Y, ZhangY MoS et al (2022) Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study. Ann Rheum Dis 81:e43. https://doi.org/10.1136/annrheumdis-2020-217313

    Article  PubMed  Google Scholar 

  33. Poddubnyy D, Sieper J (2020) Treatment of axial spondyloarthritis: what does the future hold? Curr Rheumatol Rep 22:47. https://doi.org/10.1007/s11926-020-00924-5

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kao CM, Wang JS, Ho WL et al (2022) Factors associated with the risk of major adverse cardiovascular events in patients with ankylosing spondylitis: a nationwide, population-based case-control study. Int J Environ Res Public Health 19:4098. https://doi.org/10.3390/ijerph19074098

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Atzeni F, Nucera V, Galloway J, Zoltán S, Nurmohamed M (2020) Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. Expert Opin Biol Ther 20:517–524. https://doi.org/10.1080/14712598.2020.1704727

    Article  CAS  PubMed  Google Scholar 

  36. Chan SCW, Teo CK, Li PH, Lau KK, Lau CS, Chung HY (2021) Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs. Ther Adv Musculoskelet Dis 13:1759720X211032444. https://doi.org/10.1177/1759720X211032444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM et al (2017) Fat mass lowers the response to tumor necrosis factor-α blockers in patients with ankylosing spondylitis. J Rheumatol 44:1355–1361. https://doi.org/10.3899/jrheum.170094

    Article  CAS  PubMed  Google Scholar 

  38. Gwinnutt JM, Wieczorek M, Cavalli G et al (2021) Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open 8:e002168. https://doi.org/10.1136/rmdopen-2021-002168

    Article  Google Scholar 

  39. Michelsen B, Berget KT, Kavanaugh A, Haugeberg G (2022) Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: results from a Norwegian cross-sectional observational study. Rheumatol Ther 9:1171–1179. https://doi.org/10.1007/s40744-022-00464-7

    Article  PubMed  PubMed Central  Google Scholar 

  40. Wieczorek M, Gwinnutt JM, Ransay-Colle M et al (2022) Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open 8:e002170. https://doi.org/10.1136/rmdopen-2021-002170

    Article  PubMed  PubMed Central  Google Scholar 

  41. Bodur H, Yurdakul FG, Ataman S et al (2022) Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. Clin Rheumatol 41:2053–2063. https://doi.org/10.1007/s10067-022-06145-8

    Article  PubMed  Google Scholar 

  42. Michelsen B, Berget KT, Loge JH, Kavanaugh A, Haugeberg G (2022) Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. PLoS ONE 17:e0266816. https://doi.org/10.1371/journal.pone.0266816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Merola JF, McInnes IB, Deodhar AA et al (2022) Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatol Ther 9:935–955. https://doi.org/10.1007/s40744-022-00434-z

    Article  PubMed  PubMed Central  Google Scholar 

  44. van der Heijde D, Song IH, Pangan AL et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 394:2108–2117. https://doi.org/10.1016/S0140-6736(19)32534-6

    Article  PubMed  Google Scholar 

  45. Deodhar A, Van den Bosch F, Poddubnyy D et al (2022) Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400:369–379. https://doi.org/10.1016/S0140-6736(22)01212-0

    Article  CAS  PubMed  Google Scholar 

  46. McInnes IB, Kato K, Magrey M et al (2021) Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 7:e001838. https://doi.org/10.1136/rmdopen-2021-001838. (Erratum in: RMD Open. 2021 Nov;7(3).)

    Article  PubMed  PubMed Central  Google Scholar 

  47. Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326. https://doi.org/10.1056/NEJMoa2109927

    Article  CAS  PubMed  Google Scholar 

  48. Castañeda S, Vicente-Rabaneda EF, García-Castañeda N et al (2020) Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. Expert Rev Clin Immunol 16:23–36. https://doi.org/10.1080/1744666X.2019.1699058

    Article  PubMed  Google Scholar 

  49. Yagensky V, Schirmer M (2022) Cardiovascular risks and risk stratification in inflammatory joint diseases: a cross-sectional study. Front Med (Lausanne) 9:786776. https://doi.org/10.3389/fmed.2022.786776

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Türkiye

    Hatice Bodur

Authors
  1. Hatice Bodur
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design: HB. Acquisition of data: HB. Analysis and interpretation of data: HB. Drafting of manuscript: HB. Literature search: HB.

Corresponding author

Correspondence to Hatice Bodur.

Ethics declarations

Conflict of interest

The author declares that there is no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Part of the Topical Collection entitled ‘Cardiovascular Issues in Rheumatic Diseases’

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bodur, H. Cardiovascular comorbidities in spondyloarthritis. Clin Rheumatol 42, 2611–2620 (2023). https://doi.org/10.1007/s10067-022-06473-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-022-06473-9

Keywords

Search

Navigation